TLIS insider filings

Talis Biomedical Corp — 43 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-09-09. Screen TLIS transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for TLIS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Talis Biomedical Corp

FiledFormInsiderReported transactionsSource
2024-09-094Leonard Braden Michael — 10% ownerPurchase (P): 5,100 @ $1.40 · Purchase (P): 25,000 @ $1.48EDGAR
2024-09-054Leonard Braden Michael — 10% ownerPurchase (P): 500 @ $4EDGAR
2024-09-044Leonard Braden Michael — 10% ownerPurchase (P): 151 @ $4.25EDGAR
2024-08-284Leonard Braden Michael — 10% ownerPurchase (P): 13,167 @ $3.90 · Purchase (P): 1,215 @ $3.96EDGAR
2023-08-024Lukowiak Andrew A — PresidentGrant/award (A): 30,575 (derivative) @ $0EDGAR
2023-07-184Markovich Rebecca — Interim CFOGrant/award (A): 13,071 (derivative) @ $0EDGAR
2023-06-134BAKER BROS. ADVISORS LP — Director, 10% owner
667, L.P. — Director, 10% owner
BAKER JULIAN — Director, 10% owner
BAKER FELIX — Director, 10% owner
Baker Bros. Advisors (GP) LLC — Director, 10% owner
Baker Brothers Life Sciences LP — Director, 10% owner
Grant/award (A): 23,685 (derivative) @ $0 · Grant/award (A): 23,685 (derivative) @ $0EDGAR
2023-06-124Gilliam Melissa — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2023-06-124Ismagilov Rustem F. — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2023-06-124Posard Matthew L. — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2023-06-124Dreismann Heinrich — DirectorGrant/award (A): 5,466 (derivative) @ $0EDGAR
2023-06-124Scott Randal W. — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2023-06-124Popovits Kimberly J — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2023-05-234Dreismann Heinrich — DirectorGrant/award (A): 190,000 (derivative) @ $0EDGAR
2023-04-114Kelley Robert J. — Chief Executive Officer, DirectorGrant/award (A): 500,000 (derivative) @ $0EDGAR
2023-04-114Moody John Roger Jr — Chief Financial OfficerGrant/award (A): 300,000 (derivative) @ $0EDGAR
2022-06-134Ismagilov Rustem F. — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2022-06-134Gilliam Melissa — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2022-06-134Posard Matthew L. — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2022-06-134Scott Randal W. — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2022-06-134Popovits Kimberly J — DirectorGrant/award (A): 95,000 (derivative) @ $0EDGAR
2022-06-134BAKER BROS. ADVISORS LP — Director, 10% owner
667, L.P. — Director, 10% owner
BAKER JULIAN — Director, 10% owner
BAKER FELIX — Director, 10% owner
Baker Bros. Advisors (GP) LLC — Director, 10% owner
Baker Brothers Life Sciences LP — Director, 10% owner
Grant/award (A): 95,000 (derivative) @ $0EDGAR
2022-06-024Kelley Robert J. — Chief Executive Officer, DirectorGrant/award (A): 723,560 (derivative) @ $0EDGAR
2022-06-024Moody John Roger Jr — Chief Financial OfficerGrant/award (A): 500,000 (derivative) @ $0EDGAR
2021-12-094Kelley Robert J. — Chief Executive Officer, DirectorGrant/award (A): 450,000 (derivative) @ $0EDGAR
2021-12-024Blaser Brian J — President and CEO, DirectorGrant/award (A): 750,000 (derivative) @ $0 · Grant/award (A): 625,000 (derivative) @ $0EDGAR
2021-11-194BAKER BROS. ADVISORS LP — Director, 10% owner
667, L.P. — Director, 10% owner
Baker Bros. Advisors (GP) LLC — Director, 10% owner
BAKER JULIAN — Director, 10% owner
BAKER FELIX — Director, 10% owner
Baker Brothers Life Sciences LP — Director, 10% owner
Purchase (P): 50,000 @ $4.37EDGAR
2021-10-054Liu Douglas — Chief Operating OfficerGrant/award (A): 200,000 (derivative)EDGAR
2021-10-054Kelley Robert J. — Chief Commercial OfficerGrant/award (A): 130,000 (derivative)EDGAR
2021-10-054Moody John Roger Jr — Chief Financial OfficerGrant/award (A): 130,000 (derivative)EDGAR
2021-08-314Popovits Kimberly J — Interim CEOGrant/award (A): 550,000 (derivative) @ $0EDGAR
2021-08-174Ramakrishnan RameshOption exercise (M): 43,614 @ $1.50 · Option exercise (M): 8,741 @ $1.50 · Sale (S): 27,502 @ $7.66 · Option exercise (M): 43,614 (derivative) @ $0 · Option exercise (M): 8,741 (derivative) @ $0EDGAR
2021-05-184Scott Randal W. — DirectorPurchase (P): 9,000 @ $10.16 · Purchase (P): 11,000 @ $10.11EDGAR
2021-03-184HILLEMAN JERYL L — DirectorGrant/award (A): 35,112 (derivative) @ $0EDGAR
2021-02-194Ramakrishnan Ramesh — Sr. Vice President, R&DPurchase (P): 1,000 @ $16EDGAR
2021-02-194Liu Douglas — Sr. Vice President, OperationsPurchase (P): 4,000 @ $16EDGAR
2021-02-194Flick Karen E. — Chief of Staff, Sr. VP, LegalPurchase (P): 2,000 @ $16EDGAR
2021-02-194Coe Brian — Chief Executive Officer, DirectorConversion (C): 15,082 · Conversion (C): 8,416 · Conversion (C): 7,433 · Conversion (C): 21,568 (derivative) @ $0 · Conversion (C): 12,035 (derivative) @ $0 · Conversion (C): 10,630 (derivative) @ $0EDGAR
2021-02-194Posard Matthew L. — DirectorPurchase (P): 62,500 @ $16EDGAR
2021-02-194Moody John Roger Jr — Chief Financial OfficerPurchase (P): 1,700 @ $16EDGAR
2021-02-194Scott Randal W. — DirectorConversion (C): 752,897 · Conversion (C): 334,546 · Conversion (C): 302,621 · Purchase (P): 312,500 @ $16 · Conversion (C): 1,076,643 (derivative) @ $0 · Conversion (C): 478,402 (derivative) @ $0 · +1 moreEDGAR
2021-02-194Popovits Kimberly J — DirectorConversion (C): 22,041 · Conversion (C): 209,790 · Purchase (P): 5,300 @ $16 · Conversion (C): 92,057 · Conversion (C): 89,968 · Conversion (C): 31,519 (derivative) @ $0 · +3 moreEDGAR
2021-02-194BAKER BROS. ADVISORS LP — Director, 10% owner
667, L.P. — Director, 10% owner
Baker Bros. Advisors (GP) LLC — Director, 10% owner
Baker Brothers Life Sciences LP — Director, 10% owner
BAKER FELIX — Director, 10% owner
BAKER JULIAN — Director, 10% owner
Purchase (P): 457,462 @ $16 · Purchase (P): 5,792,538 @ $16 · Grant/award (A): 767,106 (derivative) @ $8.55 · Grant/award (A): 9,191,433 (derivative) @ $8.55 · Option exercise (M): 4,975 (derivative) · Option exercise (M): 963,490 (derivative) · +18 moreEDGAR

Recent 8-K events — Talis Biomedical Corp

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2024-09-178-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2024-09-068-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2024-09-058-K/A1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2024-09-038-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2024-08-238-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9.01 — Financial Statements and Exhibits
EDGAR
2024-08-068-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
2024-06-258-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2024-06-038-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2024-05-038-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2024-04-118-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=TLIS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs